Alopecia universalis
Therapeutic area
Dermatology
Rare disease
No
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Alopecia universalis
- Therapeutic area
- Dermatology
- alopecia universalis
- AU
- All therapeutic areas
- Dermatology
- Severity
- Unknown
- Genetic
- Hereditary
- MONDO ID
- MONDO:0800198
- Parent condition
- MONDO:0003847
Related records
Broader conditions (11)
- Alopecia
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disorder of pilosebaceous unit
- Hair anomaly
- Hereditary disease
- Human disease
- Integumentary system disorder
- Skin appendage disorder
Trials (31)
- A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
- A Randomised Control Trial of Integrative Cognitive Behavioural Therapy for Alopecia
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
- Alopecia Areata Registry
- ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
- Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
- Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
- Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
- Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
- Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
- Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
- Long-Term PF-06651600 for the Treatment of Alopecia Areata
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
- PF-06651600 for the Treatment of Alopecia Areata
- Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
- Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
- PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
- Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation